Spanish media coverage this month points to a broad shift in how Alzheimer's disease is being approached, moving from symptom-based diagnosis toward precision medicine. Revista Pharma Market reported on the advances reshaping this field, while several other Spanish outlets described the same trend from different angles.
According to Diario de Sevilla, Hospital San Agustín has introduced a pioneering test that detects Alzheimer's through a blood analysis. Diario Córdoba reported that neurologist Eduardo Agüera, based in Córdoba, said he hopes the Reina Sofía hospital will soon have a blood biomarker available to diagnose Alzheimer's in its early phase.
PR Noticias framed the wider change as a move from diagnosis by symptoms to precision medicine. Infosalus reported that SEMNIM, Spain's nuclear medicine society, stressed that nuclear medicine plays a key role in selecting which patients are suitable for the new Alzheimer's drugs.
Taken together, the reports describe two connected developments: simpler tools for finding the disease earlier, and a growing need to identify the right patients before treatment begins. The blood test at Hospital San Agustín and the biomarker Agüera hopes to see in Córdoba sit on the diagnostic side, while SEMNIM's position addresses who should receive the newer therapies.
The material does not include figures on accuracy, cost or availability for the blood test, nor details on which drugs SEMNIM was referring to, so those points remain open.
What to watch next: whether blood-based biomarkers spread to more Spanish hospitals and how patient selection for the new Alzheimer's drugs develops in practice.